Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Various Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults

NCT03162614 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03162614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03162614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Various Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
May 24, 2017
Completion date
September 24, 2018
Enrollment
154 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria